Valuation: Amplia Therapeutics Limited

Market Cap 6.16Cr 4.4Cr 3.81Cr 3.59Cr 3.25Cr 6.11Cr 420.11Cr 43Cr 17Cr 213.97Cr 17Cr 16Cr 678.63Cr P/E 2027 *
-5.22x
P/E 2028 * -17.1x
Enterprise Value 4.37Cr 3.12Cr 2.7Cr 2.55Cr 2.31Cr 4.34Cr 298.03Cr 30Cr 12Cr 151.79Cr 12Cr 11Cr 481.42Cr EV / Sales 2027 *
-
EV / Sales 2028 * 4.02x
Free-Float
90.48%
Yield 2027 *
-
Yield 2028 * -
1 week-7.69%
Current month-11.11%
1 month-17.24%
3 months+9.09%
6 months+4.35%
Current year-20.00%
1 week 0.12
Extreme 0.115
0.14
1 month 0.12
Extreme 0.115
0.16
Current year 0.1
Extreme 0.1
0.28
1 year 0.1
Extreme 0.1
0.28
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 05/12/2022
Director of Finance/CFO - 01/10/2021
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Director/Board Member 70 02/09/2015
Chairman - 25/05/2018
Chairman - 30/06/2026
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/25 Exercice

Chairman

7,50,000 0.1933%
08/09/25 Free

Founder

4,47,000 0.1152%
08/09/25 Exercice

Director

5,35,000 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-7.69%-27.27%+48.15% 4.42Cr
+5.04%+3.27%+50.62%+105.43% 6.69TCr
+1.64%-2.89%+34.67%+80.49% 6.2TCr
-3.18%-0.78%-14.14%+376.43% 2.83TCr
+4.55%-0.08%+34.70%+17.28% 2.46TCr
+2.20%-4.72%+2.19%-12.71% 2.43TCr
+1.15%-2.26%+17.56%-16.53% 1.94TCr
-7.03%-9.16%+161.91%+303.00% 1.68TCr
+3.44%-1.68%-5.00%+541.17% 1.42TCr
+4.96%+4.63%-2.75%+879.79% 1.4TCr
Average +1.28%-4.32%+25.25%+232.25% 2.7TCr
Weighted average by Cap. +1.99%-2.84%+33.24%+175.82%

Financials

2027 *2028 *
Net sales - 95L 67.83L 58.71L 55.41L 50.19L 94.27L 65Cr 6.61Cr 2.55Cr 33Cr 2.55Cr 2.49Cr 104.66Cr
Net income -1.16Cr -82.83L -71.69L -67.66L -61.28L -1.15Cr -79Cr -8.08Cr -3.11Cr -40Cr -3.11Cr -3.04Cr -127.8Cr -41L -29.28L -25.34L -23.92L -21.66L -40.69L -28Cr -2.85Cr -1.1Cr -14Cr -1.1Cr -1.07Cr -45Cr
Net Debt -1.79Cr -1.28Cr -1.11Cr -1.04Cr -94.57L -1.78Cr -122.08Cr -12Cr -4.8Cr -62Cr -4.8Cr -4.69Cr -197.21Cr -2.34Cr -1.67Cr -1.45Cr -1.36Cr -1.24Cr -2.32Cr -159.6Cr -16Cr -6.28Cr -81Cr -6.27Cr -6.14Cr -257.8Cr
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
14/26/14 A$0.1200 0.00% 2,49,146
11/26/11 A$0.1200 0.00% 9,16,457
10/26/10 A$0.1200 -7.69% 5,21,229
09/26/09 A$0.1300 0.00% 4,48,319
08/26/08 A$0.1300 0.00% 10,40,026
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1200AUD
Average target price
0.4200AUD
Spread / Average Target
+250.00%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!